Piper Jaffray analyst Matt O’Brien lowered his price target on Nuvectra to $20 after its Q4 results, saying the new price target accounts for the divestiture of NeuroNexus and a modest push out of Virtis approval in his model. The analyst is also keeping his Overweight rating, noting that the company is headed for another year of increased share in the spinal cord stimulation market with expectations of adding another 15-20 reps to its sales force this year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.